TradingKey

關於 Scholar Rock Holding Corp 公司

Scholar Rock Holding Corporation 是一家生物製藥公司。該公司專注於發現、開發和提供用於治療嚴重疾病的藥物，其中蛋白質生長因子的信號傳導起着根本性的作用。其轉化生長因子β (TGFb) 超家族生物學、其生長因子激活的新型分子機制使該公司能夠開發專有平臺，用於開發局部和選擇性靶向前體的單克隆抗體。其候選產品 apitegromab 是一種選擇性、完全人源化單克隆抗體，其作用機制可抑制骨骼肌中生長因子肌生長抑制素的激活。Apitegromab 正在開發爲首個用於治療脊髓性肌萎縮症 (SMA) 的肌肉靶向療法。其另一個候選產品 SRK-181 是一種選擇性抑制潛伏性 TGFb 激活的抑制劑，正在開發用於治療癌症。

公司簡介

公司代碼SRRK

公司名稱Scholar Rock Holding Corp

上市日期May 24, 2018

CEOMr. David L. Hallal

員工數量196

證券類型Ordinary Share

年結日May 24

公司地址301 Binney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02142

電話18572593860

網址https://scholarrock.com/

公司代碼SRRK

上市日期May 24, 2018

CEOMr. David L. Hallal

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. David L. Hallal

Chairman of the Board, Chief Executive Officer

1.80M

+493.27%

Dr. Akshay K. Vaishnaw, M.D., Ph.D.

President - Research & Development, Director

616.21K

-1.08%

Mr. Vikas Sinha, CPA

Chief Financial Officer

600.00K

--

Ms. Caryn Parlavecchio

Chief Human Resources Officer

157.64K

-3.78%

Ms. Junlin Ho, J.D.

General Counsel, Corporate Secretary

96.29K

+1.19%

Ms. Tracey Sacco

Chief Commercial Officer

22.46K

--

Ms. Kristina M. Burow

Independent Director

21.07K

+11.85%

Ms. Katie Peng

Independent Director

19.27K

-13.59%

Dr. Mo Qatanani, Ph.D.

Chief Scientific Officer

16.59K

-18.11%

Mr. Joshua Reed

Independent Director

15.73K

+16.53%

名稱

名稱/職務

職務

持股

持股變動

Mr. David L. Hallal

Chairman of the Board, Chief Executive Officer

1.80M

+493.27%

Dr. Akshay K. Vaishnaw, M.D., Ph.D.

President - Research & Development, Director

616.21K

-1.08%

Mr. Vikas Sinha, CPA

Chief Financial Officer

600.00K

--

Ms. Caryn Parlavecchio

Chief Human Resources Officer

157.64K

-3.78%

Ms. Junlin Ho, J.D.

General Counsel, Corporate Secretary

96.29K

+1.19%

Ms. Tracey Sacco

Chief Commercial Officer

22.46K

--

收入明細

FY2024

暫無數據

地區USD

名稱

營收

佔比

United States

0.00

0.00%

業務

地區

暫無數據

股東統計

更新時間: 5月16日週五

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

14.48%

Invus Public Equities Advisors, LLC

9.74%

T. Rowe Price Associates, Inc.

9.27%

BlackRock Institutional Trust Company, N.A.

6.35%

Samsara BioCapital, LLC

5.91%

Other

54.24%

持股股東

佔比

Fidelity Management & Research Company LLC

14.48%

Invus Public Equities Advisors, LLC

9.74%

T. Rowe Price Associates, Inc.

9.27%

BlackRock Institutional Trust Company, N.A.

6.35%

Samsara BioCapital, LLC

5.91%

Other

54.24%

股東類型

持股股東

佔比

Investment Advisor

61.46%

Investment Advisor/Hedge Fund

26.29%

Hedge Fund

12.66%

Venture Capital

12.08%

Individual Investor

4.54%

Research Firm

2.75%

Sovereign Wealth Fund

2.10%

Pension Fund

1.07%

Private Equity

0.32%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

464

118.51M

124.82%

+4.05M

2025Q1

456

113.90M

119.97%

-666.42K

2024Q4

421

111.65M

118.02%

+13.32M

2024Q3

371

94.78M

117.45%

-2.79M

2024Q2

357

92.97M

115.37%

-3.23M

2024Q1

328

91.48M

116.64%

-131.69K

2023Q4

308

87.39M

122.16%

+15.93M

2023Q3

283

62.18M

111.86%

-162.68K

2023Q2

284

59.23M

108.43%

+2.68M

2023Q1

299

54.63M

105.29%

-1.64M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

13.75M

14.48%

+159.23K

+1.17%

Mar 31, 2025

Invus Public Equities Advisors, LLC

9.25M

9.74%

--

Mar 31, 2025

T. Rowe Price Associates, Inc.

8.81M

9.27%

-395.30K

-4.30%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.03M

6.35%

+96.10K

+1.62%

Mar 31, 2025

Samsara BioCapital, LLC

5.61M

5.91%

--

Mar 31, 2025

The Vanguard Group, Inc.

4.83M

5.09%

+98.76K

+2.09%

Mar 31, 2025

Redmile Group, LLC

4.40M

4.63%

-151.60K

-3.33%

Mar 31, 2025

State Street Global Advisors (US)

3.13M

3.3%

+494.85K

+18.75%

Mar 31, 2025

Eventide Asset Management, LLC

2.66M

2.8%

+2.37K

+0.09%

Mar 31, 2025

Polar Capital LLP

2.58M

2.72%

-125.00K

-4.62%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

4.55%

Roundhill GLP-1 & Weight Loss ETF

2.23%

Tema Neuroscience and Mental Health ETF

1.45%

Virtus LifeSci Biotech Clinical Trials ETF

0.96%

SPDR S&P Biotech ETF

0.9%

Tema Heart & Health ETF

0.61%

Direxion Daily S&P Biotech Bull 3X Shares

0.51%

First Trust NASDAQ Pharmaceuticals ETF

0.51%

ProShares Ultra Nasdaq Biotechnology

0.37%

Invesco Nasdaq Biotechnology ETF

0.37%

iShares Neuroscience and Healthcare ETF

佔比4.55%

Roundhill GLP-1 & Weight Loss ETF

佔比2.23%

Tema Neuroscience and Mental Health ETF

佔比1.45%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.96%

SPDR S&P Biotech ETF

佔比0.9%

Tema Heart & Health ETF

佔比0.61%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.51%

First Trust NASDAQ Pharmaceuticals ETF

佔比0.51%

ProShares Ultra Nasdaq Biotechnology

佔比0.37%

Invesco Nasdaq Biotechnology ETF

佔比0.37%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Scholar Rock Holding Corp

36.520USD

Scholar Rock Holding Corp

36.520

概覽

公司

財務